SHINE and C-Ray Secure Exclusive Lu-177 Distribution Deal for China
Event summary
- SHINE Technologies has named C-Ray Therapeutics as its exclusive distributor of non-carrier-added lutetium-177 (n.c.a. Lu-177) in mainland China, excluding pre-existing partnerships.
- C-Ray will supply SHINE's n.c.a. Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare institutions from its 28,000-square-meter Chengdu facility.
- SHINE's Cassiopeia facility, one of North America's largest n.c.a. Lu-177 production sites, will supply C-Ray under terms meeting both Chinese and U.S. regulatory standards.
- C-Ray supports 30+ radioisotopes and has delivered 70+ projects, including 5 programs at IND or IND-enabling stage, 5 in clinical supply, and 2 in Phase III clinical trials.
The big picture
This partnership addresses a critical supply gap in one of oncology's fastest-growing markets, ensuring reliable access to a cornerstone isotope for targeted radiopharmaceutical therapy. It underscores the strategic importance of securing diverse isotope supply chains to support pipeline innovation and expand patient access to life-saving therapies. The deal also highlights the growing collaboration between U.S. and Chinese firms in the radiopharmaceutical sector, driven by regulatory and market demands.
What we're watching
- Supply Chain Dynamics
- How SHINE's ability to serve growing demand for n.c.a. Lu-177 in China will affect its supply for customers in the U.S. and other global markets.
- Regulatory Compliance
- Whether SHINE can successfully support Chinese developers through the National Medical Products Administration (NMPA) process.
- Market Penetration
- The pace at which C-Ray can leverage its integrated platform to translate premium isotope supply into real patient outcomes and accelerated clinical translation across the industry.
Related topics